KORU Medical Systems Inc（KRMD）資訊與事件KRMDKORU Medical Systems Inc

Company Reiterates Positive EBITDA Outlook for FY26

Reiterates positive adjusted EBITDA for FY26. Sees FY26 gross margin between 62%-64%. Sees year end cash balance greater than $7.5M to account for the technology acquisition.

Koru Reports Q2 Revenue of $12.0M, Exceeding Expectations

Reports Q2 revenue $12.0M, consensus $11.62M. Cash and cash equivalents were $8.3M as of June 30, reflecting cash usage of $0.5M in Q2 of 2026. "We delivered record revenue, improved gross margins and generated positive net income for the quarter, all of which demonstrate our ability to drive durable and profitable growth in the subcutaneous drug delivery market," said Adam Kalbermatten, CEO. "We also acquired a technology asset, representing a strategic investment in connected monitoring potential to further enhance the patient experience and differentiate Koru's value proposition to our partners. Looking ahead for the remainder of 2026, we expect our international core growth to moderate as we navigate regional launch dynamics in specific European markets converting to pre-filled syringes. We remain confident in the size of our international opportunity and view capturing this business only as a matter of timing. Additionally, we have withdrawn our Phesgo(R) 510(k) application and shifted our U.S. oncology strategy to focus on alternative molecules with higher infusion volumes. Overall, we are pleased with our performance in the quarter and are focused on executing our growth strategy with operational discipline to drive durable value creation."

Koru Medical Reports Q1 Revenue of $11.77M

Koru Medical reports Q1 revenue $11.77M, consensus $11.28M